Welcome to our dedicated page for Transmedics Group SEC filings (Ticker: TMDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
TransMedics Group, Inc. filings document a Nasdaq-listed medical technology company built around the Organ Care System, National OCS Program and related transplant logistics services for lung, heart and liver transplantation. Its 8-K reports furnish operating results, guidance, tax valuation allowance disclosures and business drivers such as OCS case utilization, logistics revenue and aircraft assets.
Other filings cover material agreements, including headquarters facilities and completed aircraft acquisitions, as well as executive transitions, compensatory arrangements, inducement awards and proxy-governance matters. The company's disclosures also describe its common stock listing, board and shareholder voting matters, executive compensation, clinical program updates and FDA-related device disclosures.
TransMedics Group, Inc. reported the results of its 2026 Annual Meeting of Shareholders. Shareholders elected eight directors, including Waleed Hassanein, M.D. and James R. Tobin, to serve until the 2027 annual meeting or until successors are elected.
They approved, on a non-binding advisory basis, the compensation of the company’s named executive officers, with 22,871,647 votes in favor, 1,161,181 against and 30,895 abstentions. Shareholders also approved an amendment to the Amended and Restated TransMedics Group, Inc. 2019 Stock Incentive Plan, with 17,265,369 votes for and 6,758,882 against.
In addition, shareholders ratified the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 28,030,696 votes for, 648,359 against and 17,653 abstentions.
TransMedics Group, Inc. reported net revenue of $173.9 million for the quarter ended March 31, 2026, up from $143.5 million a year earlier, driven mainly by strong U.S. liver transplant activity. U.S. OCS liver revenue rose to $139.0 million from $108.7 million, while heart and lung revenue were roughly flat to down slightly.
Gross profit increased to $101.2 million, but higher research and development and selling, general and administrative expenses reduced income from operations to $13.3 million from $27.4 million. Net income declined to $7.3 million (diluted EPS $0.20) from $25.7 million (diluted EPS $0.70).
The company ended the quarter with $480.2 million in cash and restricted cash and total assets of $1.43 billion, reflecting recognition of a large $334.5 million finance lease right-of-use asset for its new Somerville, Massachusetts headquarters. Operating cash flow improved to $24.5 million, while capital expenditures were $36.7 million.
TransMedics Group, Inc. reported first quarter 2026 revenue of $173.9 million, up 21% from the prior year, driven mainly by greater use of its Organ Care System for liver and heart in the National OCS Program and growth in logistics services.
Profitability declined as gross margin slipped to 58% from 61% and operating expenses rose to $87.9 million from $60.8 million, reflecting higher research and development and broader investment to support growth. Income from operations fell to $13.3 million from $27.4 million, and net income dropped to $7.3 million with diluted earnings per share of $0.20, compared with $0.70 a year earlier.
On a non-GAAP basis, adjusted income from operations was $18.1 million and adjusted diluted EPS was $0.30, both down from last year. The company reiterated its full-year 2026 revenue outlook of $727–$757 million, implying 20–25% growth, and reported cash of $461.7 million. Management highlighted expansion of its aviation fleet to 22 owned aircraft, a planned investment in Germany-based PAD Aviation to build a European transplant logistics network, and progress on programs such as ENHANCE Heart, DENOVO Lung, the NOP model in Europe, OCS Kidney, and the new CHOPS preservation system.
TransMedics Group Inc disclosed that Vanguard Capital Management beneficially owns 1,737,137 shares of common stock, representing 5.06% of the class. The filing states Vanguard has sole dispositive power over 1,737,137 shares and sole voting power over 258,985 shares. The statement is signed by Ashley Grim on 04/30/2026.
TransMedics Group Inc reports a Schedule 13G filing by Vanguard Portfolio Management holding 1,949,420 shares of Common Stock, representing 5.68% of the class. The filing shows sole voting power for 29,885 shares and sole dispositive power over 1,949,420 shares as reported.
The filing names Vanguard Portfolio Management LLC and affiliated entities as the reporting persons and is signed on 04/29/2026.
TransMedics Group, Inc. presents its 2026 annual meeting proxy, highlighting strong 2025 performance and key governance items. The company reports $605.5 million in 2025 revenue, a 37% increase, driven by more than 5,100 U.S. OCS transplants and expanding use in liver and heart.
2025 was the first full year of positive cash flow, generating $152 million, and operating margin expanded to 18% from 8.5% in 2024. Management emphasizes a self-funding growth model, continued investment in its ENHANCE heart and DENOVO lung clinical programs, and development of its OCS Generation 3.0 platforms, including kidney.
Shareholders are asked to elect eight directors, approve an advisory “say on pay” vote for named executive officers, amend the 2019 Stock Incentive Plan, and ratify PricewaterhouseCoopers LLP as independent auditor. The proxy also details non-employee director pay, increased RSU-based equity awards, and executive pay structures that are heavily performance- and equity-based.
TransMedics Group Inc Schedule 13G/A reports that The Vanguard Group beneficially owns 0 shares of Common Stock, representing 0% of the class. The filing explains an internal realignment effective January 12, 2026 under SEC Release No. 34-39538, with certain Vanguard subsidiaries reporting ownership separately.
The filing is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026. It states Vanguard and its managed accounts retain rights to dividends or proceeds as described, while no single other person holds more than 5%.
TransMedics Group, Inc. officer Matthew S. Forsyth filed an initial Form 3 insider ownership report. This filing establishes him as a reporting officer of the company. The data provided shows no reported purchases, sales, option exercises, gifts, or other insider transactions at this time.
TransMedics Group, Inc. director Stephanie Lovell reported an open-market sale of common stock. On March 4, 2026, she sold 1,193 shares of TransMedics common stock at a price of $149.62 per share. After this transaction, she directly owned 2,866 shares of the company’s common stock.